Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magrolimab + Bevacizumab + FOLFIRI vs Bevacizumab + FOLFIRI in Previously Treated mCRC
2022-500177-13-00Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Aug 2022
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial of magrolimab in metastatic colon cancer (mCRC) (2 arms), sponsored by Gilead Sciences. Primary endpoints: Dose-limiting toxicities in safety run-in cohort, Adverse events in safety run-in cohort and 2 more. Started Aug 2022; status: completed.
02
Drugs
magrolimab
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2022-500177-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500177-13-00.